Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Jan-Stefan van der Walt, Joji Mori, Takahiro Nakayama, Kenichi Inoue, Yoshinori Ito, George W. Sledge, Yasuo Miyoshi, Tsutomu Kawaguchi, Masato Takahashi, Yoshinori Tanizawa, Masakazu Toi, Antonio Llombart-Cussac, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Sachi Sakaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-neg
Autor:
Masako Sato, Hidetoshi Kawaguchi, Satoshi Morita, Makiko Mizutani, Yoshie Hasegawa, Ken-ichi Watanabe, Yasuaki Sagara, Fumikata Hara, Takashi Morimoto, Takahiro Nakayama, Norikazu Masuda, Mitsuya Itoh, Shoichiro Ohtani, Nobuki Matsunami, Kenji Higaki, Masato Takahashi, Tetsuhiro Yoshinami
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. Methods Patients with metastatic breast cancer (MBC) treated with both anthracycline and
Autor:
Qiongchao Jiang, Bing Ou, Fengtao Liu, Jiyi Yao, Hui Zhi, Shao-Yun Hao, Xin Pan, Xiao-yun Xiao, Zizhuo Zhao, Bao-Ming Luo
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background There is an unmet need for specific and sensitive imaging techniques to assess the efficacy of breast cancer therapy, particularly Her-2-expressing cancers. Ultrasonic microbubbles are being developed for use as diagnostic and therapeutic
Autor:
Toru Watanabe
Publikováno v:
Breast Cancer (Tokyo, Japan)
Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur–uracil (UFT), tegafur–gimeracil–oteracil potassium (S-1), doxifluridine, and capecitabine. Since the 1980s, U
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background The human Y-box-binding protein 1 (YB-1) is a member of the DNA/RNA-binding family of proteins that regulates transcription and translation of genes. Previous studies suggest that YB-1 may have an oncogenic role in various cancers. In this
Publikováno v:
Breast Cancer (Tokyo, Japan)
We herein report an extremely rare case of ductal carcinoma in situ (DCIS) arising in tubular adenoma of the breast. A 33-year-old female first noticed a mass in her right breast when she was 15 years old. The tumor had not changed in size subjective
Autor:
Tarek Sahmoud, Yutaka Tokuda, Yoshiaki Rai, Hirotaka Iwase, Shozo Ohsumi, Hirofumi Mukai, Ashok Panneerselvam, Woo Chul Noh, Yoshinori Ito, Puttisak Puttawibul, Hideo Inaji, Tetiana Taran, Vichien Srimuninnimit, Hiroji Iwata, Norikazu Masuda, Takahiro Nakayama, Mona El-Hashimy, Shinzaburo Noguchi, Jun Horiguchi, Shinji Ohno, Katsumasa Kuroi, Byeong Woo Park
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR+) breast cancer refractory to letrozole or anastrozole. The safe
Autor:
Rieko Nishimura, Kenta Kojima, Natsumi Yamashita, Nami Okamoto, Shinichi Tanaka, Masakazu Satou
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background HER2 testing for samples from recurrent or metastatic disease is recommended by the 2013 update of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines and cytological analysis can be applied to
Publikováno v:
Breast Cancer (Tokyo, Japan)
Systemic therapies have been shown to effectively improve prognosis in patients with breast cancer. However, such therapies also become increasingly harmful as their duration increases, and they have adverse effects on fertility and ovarian function.
Publikováno v:
Breast Cancer (Tokyo, Japan)
The purpose of this article is to describe the current status and future perspectives of the Japan Breast Cancer Research Group (JBCRG). The JBCRG was organized in 2002, with the following purpose: to plan and promote clinical trials and basic resear